In Section A, participants will obtain unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Extra members will be enrolled on the determined monotherapy dosign program. In Phase B, participants will receive oral ruxolitinib and ABBV-744 is going to be given as "insert-on" therapy. In Phase https://murraya221lxh4.blog2news.com/profile